Online inquiry

IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8966MR)

This product GTTS-WQ8966MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL22 gene. The antibody can be applied in Inflammatory conditions research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_020525.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50616
UniProt ID Q9GZX6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8966MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13156MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04383119
GTTS-WQ3240MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARGX-113
GTTS-WQ14754MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-35
GTTS-WQ4811MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ4291MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB-054
GTTS-WQ6289MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CS-1001
GTTS-WQ2955MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ANB-011
GTTS-WQ3257MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ART621
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW